CWEB – Johnson & Johnson Beats Earnings Estimates

white-background (34)

CWEB.com – Johnson & Johnson Beats Earnings Estimates

By Leslie Cohen
Managing Editor

Johnson & Johnson (NYSE: JNJ) Johnson & Johnson’s first-quarter earnings beat and exceeded expectations on 4-17-2018. With a lot of momentum carrying from 2017 to 2018, the results were positive.

Earnings came out at: $2.06 per share vs. $2.02 per share expected. Respectively, revenue topped to $20 billion vs. $19.46 billion that was expected.

The new US tax legislation law gives J&J more flexibility to invest on a global basis and within the US. Strong investments of 30 billion dollars over a four year period will occur in new technologies that will be manufactured in the US.

Johnson & Johnson’s role as a biotech buyer gives them a fifty percent growth rate for the company. J&J’s consumer business has lagged with the other occupants in this sector. Baby care product sales fell down to $457 million from $455 million, a 3% percent decrease year-over-year when excluding currency. J&J will relaunch its baby care later this year. The millennial age group is interested more in organic products. With competition heating up from other organic companies like “The Honest Company”, J&J will introduce a line of baby care items with organic ingredients.

Sales for Xarelto, the blood thinner medication rose approximately 13 percent on an operational basis reaching only $578 million in global sales, missing analysts’ estimates of $633.7 million. Sales worldwide fell down to 18 percent, excluding a positive currency impact, to $1.34 billion, therefore missing analysts’ expectations for sales of $1.5 billion.

Remicade drug for arthritis has been under pressure with generic versions on the market. On the bright side the Food and Drug Administration approved Erleada, a drug that treats non-metastatic castration-resistant prostate cancer.

Chief Financial Officer Dominic Caruso CFO is announcing his retirement from his 12 year tenure at Johnson & Johnson.

ChartJNJ data by YCharts


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.